

## Billing and Coding Guide for SUBLOCADE<sup>®</sup> (buprenorphine extended-release)

**WARNING: RISK OF SERIOUS HARM OR DEATH WITH INTRAVENOUS ADMINISTRATION; SUBLOCADE RISK EVALUATION AND MITIGATION STRATEGY**

- Serious harm or death could result if administered intravenously. SUBLOCADE forms a solid mass upon contact with body fluids and may cause occlusion, local tissue damage, and thrombo-embolic events, including life threatening pulmonary emboli, if administered intravenously.
- Because of the risk of serious harm or death that could result from intravenous self-administration, SUBLOCADE is only available through a restricted program called the SUBLOCADE REMS Program. Healthcare settings and pharmacies that order and dispense SUBLOCADE must be certified in this program and comply with the REMS requirements.

See accompanying full Prescribing Information, including **BOXED WARNING** and Medication Guide, or go to [www.sublocade.com](http://www.sublocade.com).

P-BAG-US-00643 EXPIRY November 2021

  
**Sublocade<sup>®</sup>**  
(buprenorphine extended-release)  
injection for subcutaneous use <sup>Ⓜ</sup>  
100mg-300mg

INSUPPORT® was created by Indivior to provide information on the access and reimbursement processes on behalf of patients seeking treatment with SUBLOCADE® (buprenorphine extended-release). INSUPPORT provides information for healthcare professionals (HCPs) and their offices in support of these patients, including:



### BENEFIT COVERAGE INFORMATION

- Conduct Benefit Investigation of the patient's insurance coverage for SUBLOCADE
- Provide information on the prior authorization and/or appeals process from the patient's health insurance provider
- Confirm product acquisition requirements from the patient's health insurance provider
- If applicable, determine eligibility\* and enroll an eligible patient for the Copay Assistance Program for SUBLOCADE, or provide alternate funding information



### FIELD REIMBURSEMENT SPECIALIST

- A local specialist that can provide in-person information about INSUPPORT, including patient insurance benefits and requirements



### INSUPPORT WEBSITE [www.insupport.com](http://www.insupport.com)

- Find information about the steps in the patient access process
- Learn more about the INSUPPORT Copay Assistance Program for SUBLOCADE\*
- Access the Provider Portal to allow electronic enrollment and case monitoring
- Access tools, informational videos, and other resources
- Locate a Field Reimbursement Specialist

\* The INSUPPORT Copay Assistance Program is valid ONLY for patients with private insurance who are prescribed SUBLOCADE for on-label use. Patients with government insurance are not eligible for the Copay Assistance Program, including, but not limited to, Medicare, Medicaid, Medigap, VA, DoD, TRICARE, CHAMPVA, or any other federally or state-funded government-assisted program. Other restrictions apply. See insert or visit [insupport.com](http://insupport.com) to view complete Terms & Conditions.

For **BOXED WARNING**, refer to front page. See accompanying full Prescribing Information, including **BOXED WARNING** and Medication Guide, or go to [www.sublocade.com](http://www.sublocade.com).

# INTERNATIONAL CLASSIFICATION OF DISEASES (ICD)-10 CODES FOR OPIOID DEPENDENCE<sup>1</sup>

SUBLOCADE (buprenorphine extended-release) is indicated for the treatment of moderate to severe opioid use disorder in patients who have initiated treatment with a transmucosal buprenorphine-containing product, followed by dose adjustment for a minimum of 7 days.

SUBLOCADE should be used as part of a complete treatment program that includes counseling and psychosocial support.

ICD-10 CODES	
<b>F11.20</b>	<b>Opioid dependence, uncomplicated</b>
<b>F11.21</b>	<b>Opioid dependence, in remission</b>
<b>F11.220</b>	<b>Opioid dependence with intoxication, uncomplicated</b>
<b>F11.221</b>	<b>Opioid dependence with intoxication, delirium</b>
<b>F11.222</b>	<b>Opioid dependence with intoxication with perceptual disturbance</b>
<b>F11.229</b>	<b>Opioid dependence with intoxication, unspecified</b>
<b>F11.24</b>	<b>Opioid dependence with intoxication with opioid induced mood disorder</b>
<b>F11.250</b>	<b>Opioid dependence with opioid-induced psychotic disorder with delusions</b>
<b>F11.251</b>	<b>Opioid dependence with opioid-induced psychotic disorder with hallucinations</b>
<b>F11.259</b>	<b>Opioid dependence with opioid-induced psychotic disorder, unspecified</b>
<b>F11.281</b>	<b>Opioid dependence with other opioid-induced sexual dysfunction</b>
<b>F11.282</b>	<b>Opioid dependence with other opioid-induced sleep disorder</b>
<b>F11.288</b>	<b>Opioid dependence with other opioid-induced disorder</b>
<b>F11.29</b>	<b>Opioid dependence with unspecified opioid-induced disorder</b>

The individual or entity submitting a claim using INSUPPORT reimbursement and coding information must ensure that all information submitted on or with the claim is accurate, complete, and applicable to the claim being filed.

The above listed codes are provided for informational, nonpromotional purposes only. Third-party coverage and reimbursement are complex and may change frequently. Providers are responsible for determining and submitting appropriate codes and charges and appropriate medical services and products in accordance with providers' independent professional judgment.

Indivior makes no representations or warranties or guarantees of any kind relating to access, coverage, or reimbursement.

The appropriateness of filing any particular claim is and remains the responsibility of that claim's submitter based on the submitter's own judgment.

# BILLING CODES

## NATIONAL DRUG CODES (NDCS)<sup>2</sup> FOR SUBLOCADE (buprenorphine extended-release) AND FORMATTING ON MEDICAL CLAIMS

NDC	MILLIGRAMS	NDC FORMAT FOR CLAIMS	NDC LOCATION ON CLAIM FORMS
12496-0100-01	100 mg	N412496010001	<ul style="list-style-type: none"><li>• CMS-1500: Box 24A</li><li>• CMS-1450: Field 42</li></ul>
12496-0300-01	300 mg	N412496030001	<ul style="list-style-type: none"><li>• CMS-1500: Box 24A</li><li>• CMS-1450: Field 42</li></ul>

## CPT<sup>3</sup> CODE<sup>4</sup>

CPT CODE	DESCRIPTION
96372	<b>Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular</b>

**SUBLOCADE should be administered by an HCP by subcutaneous injection only. Do not administer SUBLOCADE intravenously or intramuscularly.**

The individual or entity submitting a claim using INSUPPORT reimbursement and coding information must ensure that all information submitted on or with the claim is accurate, complete, and applicable to the claim being filed. The above listed codes are provided for informational, nonpromotional purposes only. The information provided is accurate on the publication date, but it should be independently verified. The appropriateness of filing any particular claim is and remains the responsibility of that claim's submitter based on the submitter's own judgment.

## PRODUCT-SPECIFIC HCPCS CODES FOR SUBLOCADE (buprenorphine extended-release)<sup>5</sup>

HCPCS CODE	DESCRIPTION	NUMBER OF UNITS
Q9991	<b>Injection, buprenorphine extended-release (Sublocade), less than or equal to 100 mg</b>	<b>1</b>
Q9992	<b>Injection, buprenorphine extended-release (Sublocade), greater than 100 mg</b>	<b>1</b>

Q codes are primarily applicable to the physician office or hospital outpatient clinic settings.

Please note that some payers, including state Medicaid programs, require HCPs to report the 11-digit HIPAA-compliant version of the NDC (5-4-2 format) for a physician-administered drug along with its HCPCS code on paper claim forms and their electronic equivalents.<sup>6</sup>

For **BOXED WARNING**, refer to front page. See accompanying full Prescribing Information, including **BOXED WARNING** and Medication Guide, or go to [www.sublocade.com](http://www.sublocade.com).

# BILLING SUBLOCADE (buprenorphine extended-release)

## G CODE DESCRIPTIONS IN OTP AND PHYSICIAN OFFICE SETTINGS<sup>7</sup>

G CODE	DESCRIPTION
<b>Weekly Codes in OTP Setting</b>	
<b>G2069</b>	Medication assisted treatment, buprenorphine (injectable); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program)
<b>G2074</b>	Medication assisted treatment, weekly bundle not including the drug, including substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program)
<b>Monthly Codes in Physician Office Setting</b>	
<b>G2086</b>	Office-based treatment for opioid use disorder, including development of the treatment plan, care coordination, individual therapy and group therapy and counseling; at least 70 minutes in the first calendar month
<b>G2087</b>	Office-based treatment for opioid use disorder, including care coordination, individual therapy and group therapy and counseling; at least 60 minutes in a subsequent calendar month

Starting in 2020, Medicare will reimburse opioid treatment programs (OTPs) with a bundled payment for opioid use disorder (OUD) treatment services.<sup>7</sup> An OTP is defined as “a program or practitioner engaged in opioid treatment of individuals with an opioid agonist medication.”<sup>8</sup> The Substance Abuse and Mental Health Services Administration (SAMHSA) certifies and requires that OTPs must:

- Be accredited by a federally-deemed accrediting body,
- Be accredited under the BHC accreditation program (if the OTP “is part of an organization accredited under a different program by The Joint Commission”), and
- Have on active patient eligible for survey.<sup>8</sup>

The table above notes the relevant G codes for an episode of care in the OTP or physician office setting. Please note the G codes are for weekly episodes of care. The table below highlights the codes and associated descriptions.

## BILLING IN MEDICARE VS OTHER PAYERS

	Claim Form	OPIOID TREATMENT PROGRAM	PHYSICIAN OFFICE	HOSPITAL OUTPATIENT
		CMS-1500	CMS-1500	CMS-1450
<b>MEDICARE<sup>6</sup></b>	<b>Professional Services</b>	<b>G2069</b>	<b>G2086 and G2087</b>	<b>96372</b>
	<b>SUBLOCADE</b>		<b>Q9991 or Q9992</b>	<b>Q9991 or Q9992</b>
<b>ALL OTHER PAYERS</b>	<b>Professional Services</b>	<b>96372</b>	<b>96372</b>	<b>96372</b>
	<b>SUBLOCADE</b>	<b>Q9991 or Q9992</b>	<b>Q9991 or Q9992</b>	<b>Q9991 or Q9992</b>

Contact your Field Reimbursement Specialist for more information or to schedule an in-office meeting.

Call INSUPPORT at **844-INSPPRT** (844-467-7778) between 8:00 AM and 8:00 PM ET.

Visit [www.insupport.com](http://www.insupport.com).

## REFERENCES

**1.** Centers for Medicare & Medicaid Services. ICD-10-CM tabular list of diseases and injuries. [https://www.cms.gov/medicare/coding/icd10/downloads/6\\_i10tab2010.pdf](https://www.cms.gov/medicare/coding/icd10/downloads/6_i10tab2010.pdf). Accessed May 30, 2019. **2.** Sublocade [package insert]. North Chesterfield, VA: Indivior Inc; 2017. **3.** CPT copyright 2018 American Medical Association. All rights reserved. CPT is a registered trademark of the American Medical Association. The AMA assumes no liability for data contained or not contained herein. **4.** American Medical Association. 2018 Professional Edition, Current Procedural Terminology (CPT). Copyright 2017 American Medical Association. 2018. All rights reserved. **5.** Centers for Medicare & Medicaid Services. Pub 100-04 Medicare Claims Processing Transmittal 4048. Quarterly Healthcare Common Procedure Coding System (HCPCS) Drug/Biological Code Changes. July 2018 Update. May 11, 2018. <https://www.cms.gov/Regulations-and-Guidance/Guidance/Transmittals/2018Downloads/R4048CP.pdf>. Accessed May 17, 2018. **6.** Centers for Medicare & Medicaid Services. Medicare Learning Network. MLN Matters® Number: SE1234. September 5, 2012. Important information concerning the Medicare crossover process and state Medicaid agency requirements for National Drug Codes (NDCs) associated with physician-administered Part B drugs. <https://www.cms.gov/Outreach-and-Education/Medicare-Learning-Network-MLN/MLNMattersArticles/downloads/se1234.pdf>. Accessed May 9, 2018. **7.** Centers for Medicare & Medicaid Services. Revisions to Payment Policies under the Medicare Physician Fee Schedule, Quality Payment Program and Other Revisions to Part B for CY 2020. <https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/PhysicianFeeSched/PFS-Federal-Regulation-Notices-Items/CMS-1715-F>. Accessed on November 25, 2019. **8.** The Joint Commission. Opioid Treatment Program (OTP) Accreditation. [https://www.jointcommission.org/facts\\_opioid\\_treatment\\_program\\_otp\\_accreditation/](https://www.jointcommission.org/facts_opioid_treatment_program_otp_accreditation/). Accessed November 25, 2019.